{
    "title": "AstraZeneca COVID drug neutralizes Omicron sub-variants in lab study",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-10634923/AstraZeneca-COVID-drug-neutralizes-Omicron-sub-variants-lab-study.html",
    "date": "2022-03-21",
    "keywords": [
        "omicron",
        "study",
        "evusheld",
        "covid19",
        "therapy",
        "week",
        "activity",
        "ba2",
        "lab",
        "virus",
        "astrazeneca",
        "march",
        "monday",
        "cocktail",
        "coronavirus",
        "subvariant",
        "impact",
        "treatment",
        "variant",
        "spike",
        "drugmaker",
        "december",
        "httpswwwbiorxivorgcontent10110120220317484787v1",
        "washington",
        "university",
        "amount",
        "load",
        "ba1",
        "ba11",
        "inflammation",
        "symptom",
        "option",
        "john",
        "head",
        "development",
        "world",
        "health",
        "organization",
        "rise",
        "problem",
        "easing",
        "risk",
        "drug",
        "regulator",
        "response",
        "disease",
        "progression",
        "immune",
        "system",
        "body",
        "case",
        "infection",
        "review",
        "pushkala",
        "aripaka",
        "bengaluru",
        "editing",
        "kalluvila",
        "aditya",
        "soni",
        "fenton"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}